Logo Image
News
All NewsContributorsMoney Matters
Media
All VideosExpert InterviewsMedical World NewsPodcastsBeyond The WallsCase Based Roundtable SeriesCase of the QuarterEyeViewGrand RoundsInsightsRapid ReadoutShortsSpecial ReportViewpointsWhat’s Your WhEYE?
Conferences
Conference CoverageConference Listing
Events
More
Publications
Digital EditionEurope Ophthalmology TimesModern RetinaSupplements and Featured Publications
CME
Partners
Resources
Job BoardSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publications
  • CME
  • Partners
  • Subscribe
  • Resources
  • AMD
  • Biosimilars
  • COVID-19
  • Cataract
    • Cataract Surgery
  • Cataract Therapeutics
  • Clinical Diagnosis
    • On the Orbital Edge
    • The Residency Report
    • iOpeners
    • NeuroOp Guru
    • IOLs: What Every Surgeon Needs to Know
  • Cornea
  • DME
  • Dry Eye
    • Dry Eye Awareness
  • Gene Therapy
  • Geographic Atrophy
  • IOL
    • IOL Advances
  • Imaging
  • Interventional Glaucoma
    • Glaucoma Awareness
    • Glaucoma Insights
    • Therapeutic Glaucoma
  • OCT
  • Ocular Allergy
  • Ocular Surface Disease
  • Optic Relief
  • Optometry
  • Pediatrics
  • Pharmacy
  • Practice Management
    • Indispensable
  • Presbyopia
  • Ptosis
  • Refractive
    • Refractive Surgery
  • Retina
  • Surgery
  • Technology
  • Therapeutics
  • Understanding Antibiotic Resistance
  • Workplace
Spotlight -
Retina
Advertisement

Ophthalmology Times: November 15, 2021

New presbyopia-correcting IOL provides spectacle independence

New presbyopia-correcting IOL provides spectacle independence

ByFilomena J. Ribeiro, MD, PhD, FEBO
November 19th 2021

Lens combines diffractive multifocal and extended depth-of-focus properties.

Artificial DMEK could help tackle endothelial donor tissue shortage

Artificial DMEK could help tackle endothelial donor tissue shortage

ByVictor A. Augustin, MD,Maximilian K. Köppe, MD,Gerd U. Auffarth, MD, PhD, FEBO
November 18th 2021

New acrylic implant provides option for patients with endothelial dysfunction.

The FDA’s approval of varenicline nasal spray 0.03 mg (Tyrvaya, Oyster Point Pharma) for the treatment of the signs and symptoms of dry eye disease (DED) brings to the management of this common condition a new therapeutic modality that is novel for both its mechanism of action and mode of administration

Varenicline nasal spray approved as a treatment for dry eye disease

ByCheryl Guttman Krader, BS, Pharm
November 17th 2021

Product stimulates basal tear production, restores tear film homeostasis, and relieves symptoms.

Advertisement
Advertisement

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

1

Polyendocrine metabolic ovarian syndrome: looking past the reproductive system to the eye

2

Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study

3

Thyroid eye disease specialists react to the FDA approval of veligrotug-vvze

4

Pterygium width may help predict corneal optical disturbance

5

Port Delivery System Therapies in Retinal Vascular Diseases

  • About
  • Advertise
  • Privacy
  • Editorial Info
  • Editorial Board
  • Terms and Conditions
  • Contact Us
  • Do Not Sell My Personal Information
  • Job Board
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Ophthalmology Times
  • Modern Retina
  • Optometry Times
  • Ophthalmology Times Europe
EyeCare Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us